日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comparison of the efficacy and safety of different thrombolytic drugs in the treatment of acute ischemic stroke within 4.5 h: a systematic review and network meta-analysis

比较不同溶栓药物治疗急性缺血性卒中4.5小时内的疗效和安全性:系统评价和网络荟萃分析

Yu, Xinmin; Liu, Jiale; Shi, Chenlei; Xue, Degang; Jiang, Yuting; Wang, Weiwei; Zhao, Miaomiao

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

HA121-28 在晚期实体瘤和 RET 融合阳性非小细胞肺癌患者中的安全性、药代动力学和疗效:一项多中心、开放标签、单臂 1/2 期试验

Ruan, Dan-Yun; Huang, Wen-Wen; Li, Yongsheng; Zhao, Yanqiu; Shi, Yehui; Jia, Yuming; Cang, Shundong; Zhang, Wei; Shi, Jianhua; Chen, Jun; Lin, Jie; Liu, Yunpeng; Xu, Jianming; Ouyang, Weiwei; Fang, Jian; Zhuang, Wu; Liu, Caigang; Bu, Qing; Li, Manxiang; Meng, Xiangjiao; Sun, Meili; Yang, Nong; Dong, Xiaorong; Pan, Yueyin; Li, Xingya; Qu, Xiujuan; Zhang, Tongmei; Yuan, Xianglin; Hu, Sheng; Guo, Wei; Li, Yalun; Li, Shengqing; Liu, Dongying; Song, Feixue; Tan, Liping; Yu, Yan; Yu, Xinmin; Zang, Aimin; Sun, Chang; Zhang, Qian; Zou, Kai; Dan, Mo; Xu, Rui-Hua; Zhao, Hongyun

Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial

一线信迪利单抗联合安罗替尼对比化疗治疗转移性非小细胞肺癌的疗效和安全性:一项II期、开放标签、随机对照试验

Chu, Tianqing; Zhong, Hua; Yu, Zhuang; Wang, Jing; Zhao, Yanqiu; Mu, Xiaoqian; Yu, Xinmin; Shi, Xun; Shi, Qingming; Guan, Maojing; Ding, Cuimin; Geng, Nan; Qian, Jialin; Han, Baohui

High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial

高剂量奥莫替尼治疗未经治疗的EGFR变异型非小细胞肺癌伴脑转移:ACHIEVE II期非随机临床试验

Li, Hui; Chen, Kaiyan; Gong, Lei; Qin, Jing; Jin, Ying; Zhou, Rongrong; Huang, Zhiyu; Xu, Yanjun; Xu, Xiaoling; He, Jingdong; Zhu, Junfei; Yu, Sizhe; Lu, Hongyang; Xu, Yujin; Yu, Xinmin; Han, Guang; Chen, Jun; Tan, Wei; Lou, Guangyuan; Ren, Biyong; Chen, Xiangqi; Zhang, Dianbao; Wang, Wenxian; Shi, Xun; Xie, Fajun; Zhao, Jun; Han, Na; Li, Bing; Fan, Yun

Microneedle Patch for In Situ Neutrophil Monitoring

用于原位中性粒细胞监测的微针贴片

Lu, Ziyi; Cai, Ruisi; Xie, Tianao; Zhao, Sheng; Juengpanich, Sarun; Topatana, Win; Li, Shijie; Cao, Jiasheng; Hu, Jiahao; Chen, Tianen; Chen, Jiachen; Yu, Jicheng; Sheng, Tao; Zhang, Wentao; Wang, Hao; You, Jiahuan; Shan, Yukai; Sun, Yuchao; Shen, Ruijing; Zhao, Zhengjie; Ji, Kangfan; Gao, Ziqi; Yu, Xinmin; Cai, Xiujun; Gu, Zhen; Zhang, Yuqi; Chen, Mingyu

First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial

一线替雷利珠单抗联合化疗治疗晚期非鳞状非小细胞肺癌:RATIONALE-304试验中PD-L1 ≥ 50%亚组分析

Lu, Shun; Wang, Jie; Yu, Yan; Yu, Xinmin; Hu, Yanping; Wangjun, Liao; Li, Xingya; Liu, Yuepeng; Li, Weidong; Qu, Xiaofei; Bao, Yuanyuan; Wang, Mengzhao

An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor

一项开放标签、单臂、II期临床试验,评估信迪利单抗联合安罗替尼治疗一线PD-(L)1抑制剂治疗后转移性非小细胞肺癌的疗效

Shi, Xun; Lin, Chen; Lou, Lishu; He, Qiong; Lou, Guangyuan; Hong, Wei; Shao, Lan; Zhao, Jun; Gu, Cuiping; Yu, Xinmin; Jin, Ying

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

一项针对晚期实体瘤患者的 I 期研究,评估 OX40 激动剂 BGB-A445 联合或不联合抗 PD-1 单克隆抗体替雷利珠单抗的疗效:剂量递增结果

Desai, Jayesh; Deva, Sanjeev; Gao, Bo; Yang, Kunyu; O'Byrne, Kenneth J; Sun, Meili; Liu, Tianshu; Meniawy, Tarek; Yu, Xinmin; Voskoboynik, Mark; Davar, Diwakar; Matos, Marco; Leaw, Shiangjiin; Rahman, Tahmina; Qu, Xiaofei; Giovinazzo, Hugh; Chen, Xin; Dong, Yan; Day, Daphne

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)

奥莫替尼与吉非替尼治疗未经治疗的 EGFR 突变晚期非小细胞肺癌患者的中枢神经系统疗效:一项随机 III 期试验 (AENEAS) 的数据

Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhi; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lu, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wancheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Weng, Jie; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Wei, Hongying; Wei, Jiawei; Zhang, Zheyu; Wu, Qiong

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

Tunlametinib (HL-085) 联合 vemurafenib 治疗 BRAF V600 突变晚期实体瘤患者:一项开放标签、单臂、多中心 I 期研究

Shi, Yuankai; Han, Xiaohong; Zhao, Qian; Zheng, YuLong; Chen, Jianhua; Yu, Xinmin; Fang, Jian; Liu, Yutao; Huang, Dingzhi; Liu, Tianshu; Shen, Hong; Luo, Suxia; Yu, Hongsheng; Cao, Yu; Zhang, Xi; Hu, Pei